AFTER 25 years of service at the US Food and Drug Administration (FDA), John Jenkins (pictured), director of the Office of New Drugs, will retire from the federal government on 06 Jan 2017.
Jenkins oversaw a staff of more than 1,000, navigating many high-profile controversies related to new drugs, while at the same time interacting with industry and other stakeholders.
During his tenure, Jenkins was responsible for setting new US standards for new drugs' safety and efficacy, overseeing the clinical testing of investigational drugs and reviewing marketing applications.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Dec 16
